STAT3 and non-small cell lung carcinoma: To deal with such resistance, Zheng et al. screened out a new STAT3 inhibitor, W2014-S, and proved its efficacy in NSCLC PDX models with abnormal STAT3 activation.195 Therefore, PDX models provide solid preclinical evidence of drug efficacy.